Explore more publications!

Technology Times New Jersey: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times New Jersey.

Press releases published on October 16, 2025

Free Psychic Reading Online & Free Psychic Chat with Real, Vetted Advisors by The Psychic Experts!
UPDATE: SINTX stärkt sein Portfolio zur Infektionsprävention mit einem neu zugelassenen US-Patent, das einen adressierbaren Markt für Antipathogene im Wert von 30 Milliarden US-Dollar abdeckt
MISE À JOUR : SINTX renforce son portefeuille de produits de prévention des infections grâce à un nouveau brevet américain couvrant un marché antipathogène potentiel de 30 milliards de dollars
KABAR TERBARU: SINTX Memperkuat Portofolio Pencegahan Infeksi dengan Paten A.S. yang Baru Disetujui yang Mencakup Pasar Antipatogenik yang Dapat Dijangkau senilai $30 Miliar
更新:シントクス (SINTX)、3,000億米ドル (約44兆3,496億3,478万円) 規模の抗病原性アドレス可能市場を対象とする新たな米国特許の許可取得により感染防止ポートフォリオを強化
KEMAS KINI: SINTX Perkukuh Portfolio Pencegahan Jangkitan dengan Paten Baharu yang Diluluskan di AS, Meliputi Pasaran Antipatogenik Bernilai AS$30 Bilion
업데이트: SINTX, 신규 미국 특허 승인으로 300억 달러 규모 항병원성 시장 공략 강화
อัปเดต: SINTX เสริมความแข็งแกร่งให้กับกลุ่มผลิตภัณฑ์ด้านการป้องกันการติดเชื้อ ด้วยสิทธิบัตรสหรัฐฯ ฉบับใหม่ที่ครอบคลุมตลาดเป้าหมายด้านสารต้านเชื้อโรคมูลค่า 3 หมื่นล้านดอลลาร…
ATUALIZAÇÃO: SINTX Fortalece Portfólio de Prevenção de Infecções com a Recente Patente nos EUA que Abrange um Mercado de US $30 bilhões Endereçável Antipatogênico
更新:SINTX 通过新获批的美国专利,强化其感染防护产品组合,该专利覆盖价值 300 亿美元的抗病原体潜在市场
最新消息:SINTX 加強預防感染產品組合並獲批新美國專利,可觸及 300 億美元抗病原市場
La subsidiaria ZenaDrone de ZenaTech realizará reuniones con miembros del Congreso para destacar su innovación en drones, seguida de la presentación de sus soluciones de drones en el Foro de Defensa AUVSI
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute
DeLeion Capital Launches as a Global Digital Asset & Financial Infrastructure Firm Bringing Institutional-Grade Solutions to Individuals, Entrepreneurs, and Enterprises
Nicola Wealth Evolves Leadership Team for Next Phase of Growth with Key Executive Appointments
聽證會取消後,Apollomics 宣佈繼續於 The Nasdaq Stock Market 維持其上市地位
Carbon Browser and Unstoppable Domains Launch .CARBON Top-Level Domain, Defining a Privacy-First Identity Layer for Web3
New Benchmark with RETEVIS RB48 Pro, Cementing 15-Year Legacy of Industrial-Grade Innovation

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions